CSL Limited
(ASX:CSL) has lifted its profit guidance by 20 per cent for fiscal 2013.
The biopharmaceutical company has lifted its forecast from 12 per cent, following a newly compiled financial forecast.
CSL’s Managing Director says the improved company outlook is largely underpinned by a number of factors including the performance of its Melbourne based subsidiary CSL Behring and a higher than expected royalty income from sales of its GARDASIL® vaccine.
In the 2012 financial year, CSL generated a net profit of $982.6 million.
